Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-06-0118PMID 16891472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

  2012cited by this paper
• Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors.

  2006cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• 5-Fluoro-2′-Deoxyuridine-Induced cdc25A Accumulation Correlates with Premature Mitotic Entry and Clonogenic Death in Human Colon Cancer Cells

  2004cited by this paper
• Book Review: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval

  2004cited by this paper
• Methods in molecular medicine

  2004cited by this paper
• Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval

  2004cited by this paper
• A novel approach to prepare a liposomal irinotecan formulations that exhibit significant therapeutic activity in vivo

  2004cited by this paper
• Determination of subcutaneous tumor size in athymic (nude) mice

  2004cited by this paper
• Assays for in vitro and in vivo synergy.

  2003cited by this paper
• Synergy Between 3′Azido-3′deoxythymidine and Paclitaxel in Human Pharynx FaDu Cells

  2003cited by this paper
• Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.

  2003cited by this paper
• Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

  2003influential reference
• Supra‐additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro

  2002cited by this paper
• Clinical translation of angiogenesis inhibitors

  2002cited by this paper
• Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

  2001cited by this paper
• In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

  2001cited by this paper
• Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants

  2001cited by this paper
• Drug synergism: its detection and applications.

  2001cited by this paper
• Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.

  2001influential reference
• Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

  2000cited by this paper
• Interaction between gemcitabine and mitomycin-C in vitro

  2000cited by this paper
• Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.

  1999cited by this paper
• Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.

  1999cited by this paper
• Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.

  1998cited by this paper
• Pharmacodynamic aspects of peptide administration biological response modifiers.

  1998cited by this paper
• Anticancer Drug Development Guide

  1997cited by this paper
• In Vivo Methods for Screening and Preclinical Testing

  1997cited by this paper
• Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo

  1997cited by this paper
• Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.

  1997cited by this paper
• Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.

  1996cited by this paper
• The search for synergy: a critical review from a response surface perspective.

  1995cited by this paper
• Novel approaches to selective treatments of human solid tumors: laboratory and clinical correlation.

  1993cited by this paper
• 5-Fluoro-2'-deoxyuridine: role of schedule in its therapeutic efficacy.

  1993cited by this paper
• Synergism and antagonism in chemotherapy

  1991cited by this paper
• The Basic Science of Oncology

  1989cited by this paper
• Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).

  1989cited by this paper
• Isobolographic, Algebraic, and Search Methods in the Analysis of Multiagent Synergy

  1988cited by this paper
• Laboratory models: some historical perspective.

  1986cited by this paper
• Tumor measurement in the nude mouse

  1986cited by this paper
• Laboratory models: some historical perspective.

  1986cited by this paper
• Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential.

  1985cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• Dose: a critical factor in cancer chemotherapy.

  1980influential reference
• EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.

  1964cited by this paper

• Liposomal Co-Formulation of Azure A and Rose Bengal Decyl Ester as a Multi-Cellular Target Approach for Photodynamic Therapy of Colorectal Cancer

  2026cites this paper
• CPX-351: From preclinical studies to future directions.

  2026cites this paper
• Synergistic targeting and stimuli-responsive drug delivery from a dual-network injectable hydrogel for enhanced breast cancer treatment.

  2026cites this paper
• Enhancing the therapeutic potential of plumbagin in breast cancer via advanced nanomedicine approaches

  2026cites this paper
• Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?

  2025cites this paper
• Polymer-based nanomedicines: Supporting multimodal approaches to glioblastoma Multiforme treatment.

  2025cites this paper
• SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations

  2025cites this paper
• Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351

  2025cites this paper
• Anti-CD33 antibody enhances liposomal co-delivery of cytarabine and daunorubicin for targeted combination chemotherapy.

  2025cites this paper
• Anticancer activity of Ilex khasiana, a rare and endemic species of holly in Northeast India, against murine lymphoma

  2025cites this paper
• Antagonistic interactions between spinosad and macrocyclic lactones in combination against larvae of the sheep blowfly, Lucilia cuprina, in vitro.

  2025cites this paper
• Ferroptosis and the cGAS-STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma.

  2025cites this paper
• Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center

  2025cites this paper
• Ratiometric Strategies in Oncology: Multifunctional Roles in Chemotherapy, Imaging, and Diagnosis.

  2025cites this paper
• Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin

  2025cites this paper
• The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety

  2025influential citation
• Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer

  2025cites this paper
• Nanomedicine Tumor Targeting

  2024cites this paper
• Remote loading in liposome: a review of current strategies and recent developments

  2024cites this paper
• Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy.

  2024cites this paper
• Co-delivery Liposomes of Irinotecan Hydrochloride and Curcumin in the Synergistic Treatment of Colorectal Cancer

  2024cites this paper
• Synchronized Codelivery of Combination Chemotherapies Intratumorally Using a Lipidic Lyotropic Liquid Crystal System.

  2024cites this paper
• Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

  2024cites this paper
• Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia.

  2024cites this paper
• A comparative safety review of targeted therapies for acute myeloid leukemia

  2023cites this paper
• Curcumin combining temozolomide formed localized nanogel for inhibition of postsurgical chemoresistant glioblastoma.

  2023cites this paper
• Recent advances in targeted therapies in acute myeloid leukemia

  2023cites this paper
• HDACIs and TKIs combinations and their liposomal delivery for cancer treatment.

  2023cites this paper
• Self-Assembly of a Linear-Dendritic Polymer Containing Cisplatin and Norcantharidin into Raspberry-like Multimicelle Clusters for the Efficient Chemotherapy of Liver Cancer.

  2023cites this paper
• Induced Vascular Normalization—Can One Force Tumors to Surrender to a Better Microenvironment?

  2023cites this paper
• Lipid-based nanoparticle-mediated combination therapy for breast cancer management: a comprehensive review

  2023cites this paper
• Ratio-dependent effects of photoactivated hypericin and manumycin A on their genotoxic and mutagenic potential.

  2023cites this paper
• Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy

  2023cites this paper
• Pediatric acute myeloid leukemia: insight into genetic landscape and novel targeted approaches.

  2023cites this paper
• Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.

  2023cites this paper
• Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer.

  2023cites this paper
• Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia

  2022cites this paper
• Co-encapsulation of flavonoids with anti-cancer drugs: a challenge ahead.

  2022cites this paper
• Co‐Delivery of Precisely Prescribed Multi‐Prodrug Combination by an Engineered Nanocarrier enables Efficient Individualized Cancer Chemotherapy

  2022cites this paper
• The effects of intermolecular interactions on the stability and in vitro drug release of daunorubicin/cytarabine co-loaded liposome.

  2022cites this paper
• In Situ Micro-Nano Conversion Augmented Tumor-Localized Immunochemotherapy.

  2022cites this paper
• CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.

  2022cites this paper
• Nanoprodrug ratiometrically integrating autophagy inhibitor and genotoxic agent for treatment of triple-negative breast cancer.

  2022cites this paper
• Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.

  2022cites this paper
• Dual Vinorelbine bitartrate and Resveratrol loaded polymeric aqueous core nanocapsules for synergistic efficacy in breast cancer

  2022cites this paper
• Targeted liposomal doxorubicin/ceramides combinations: the importance to assess the nature of drug interaction beyond bulk tumor cells.

  2022cites this paper
• Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy.

  2022cites this paper
• Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

  2022cites this paper
• Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches.

  2021cites this paper
• 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?

  2021cites this paper
• SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma

  2021cites this paper
• The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway

  2021cites this paper
• Cellular stress response to extremely low‐frequency electromagnetic fields (ELF‐EMF): An explanation for controversial effects of ELF‐EMF on apoptosis

  2021cites this paper
• Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway

  2021cites this paper
• Phenylboronic acid-functionalized co-delivery micelles with synergistic effect and down-regulation of HIF-1alpha to overcome multidrug resistance

  2021cites this paper
• Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy

  2021cites this paper
• Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective

  2021cites this paper
• Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.

  2021cites this paper
• A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’

  2021cites this paper
• Macrocyclic‐Amphiphile‐Based Self‐Assembled Nanoparticles for Ratiometric Delivery of Therapeutic Combinations to Tumors

  2021cites this paper
• Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

  2021cites this paper
• Preparation of Functional Vincristine Liposomes for Treatment of Invasive Breast Cancer

  2021cites this paper
• Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia.

  2021cites this paper
• Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer

  2020cites this paper
• Novel Therapeutic Approaches to Treat Brain Cancer Combining Cold Atmospheric Plasma, Therapeutic Prodrugs and Gold Nanoparticles

  2020cites this paper
• CPX-351 - Daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.

  2020cites this paper
• Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible

  2020cites this paper
• The effect of efflux pump inhibitors on in vitro and in vivo efficacy of solid lipid nanoparticles containing SN38

  2020cites this paper
• Insights into the Pathobiology of Secondary AML

  2020cites this paper
• DNA-Controlled Encapsulation of Small Molecules in Protein Nanoparticles.

  2020cites this paper
• Ultrasound Combined with Core Cross-Linked Nanosystem for Enhancing Penetration of Doxorubicin Prodrug/Beta-Lapachone into Tumors

  2020cites this paper
• Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

  2020cites this paper
• Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia

  2020cites this paper
• Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals.

  2020cites this paper
• Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia

  2020cites this paper
• Artificial peptides for antitumoral siRNA delivery.

  2020cites this paper
• Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

  2020cites this paper
• Synthesis of temperature/pH dual-stimuli response multicompartmental microcapsules via Pickering emulsion for preprogrammable payload release.

  2020cites this paper
• Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?

  2020cites this paper
• Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities

  2020cites this paper
• How to address second and therapy‐related acute myelogenous leukaemia

  2020cites this paper
• Combination Strategies for Targeted Delivery of Nanoparticles for Cancer Therapy

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers

  2019cites this paper
• Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia

  2019cites this paper
• Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia

  2019cites this paper
• Liposome-Based Drug Delivery for Lung Cancer

  2019cites this paper
• Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.

  2019cites this paper
• CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

  2019cites this paper
• Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies

  2019cites this paper
• Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.

  2019cites this paper
• Polymeric Core–Shell Combinatorial Nanomedicine for Synergistic Anticancer Therapy

  2019cites this paper
• Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety.

  2019cites this paper
• Nanotechnology Toward Treating Cancer

  2019cites this paper
• Synergistic Action of Gefitinib and GSK41364A Simultaneously Loaded in Ratiometrically-Engineered Polymeric Nanoparticles for Glioblastoma Multiforme

  2019cites this paper
• Genetic and epigenetic determinants of AML pathogenesis.

  2019cites this paper
• What Drives Innovation: The Canadian Touch on Liposomal Therapeutics

  2019cites this paper
• Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model.

  2019cites this paper
• A personalized approach to acute myeloid leukemia therapy: current options

  2019cites this paper
• Multifunctional Nanocarriers for Combination Cancer Therapy

  2019cites this paper
• BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers.

  2019cites this paper